Last reviewed · How we verify
NCT03652896
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma
NA trial testing anatomical liver resection in Hepatocellular Carcinoma by BCLC Stage in 60 participants. Status unknown.
30 December 2021
Quick facts
| Lead sponsor | Huazhong University of Science and Technology |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 January 2019 |
| Primary completion | 30 December 2021 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- anatomical liver resection
Conditions studied
- Hepatocellular Carcinoma by BCLC Stage — all drugs for Hepatocellular Carcinoma by BCLC Stage →
Sponsor
Huazhong University of Science and Technology
Who can join
Adults 17 to 65, any sex, with Hepatocellular Carcinoma by BCLC Stage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anatomical liver resection was widely accepted as first line curative therapy for hepatocellular carcinoma. However, number of retrospective clinical studies showed no priority of anatomical resection for hepatocellular, compared with non-anatomical resection. Surgical resection margin is a essential factor that may affect tumor prognosis. It is controversial whether adequate liver resection margin is associated with improved survival outcome in patients with hepatocellular. There was few prospective clinical trial to investigate whether anatomical liver resection is superior to non-anatomical resection or liver resection with adequate margin is superior to that with inadequate margin. This prospective clinical trial aims at fix these issues.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03652896
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of anatomical liver resection
Trials testing the same drug.
- NCT05881746 — Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness · NA · not yet recruiting
Other Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
- NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
- NCT07509866 — Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal · NA · recruiting
- NCT07326943 — Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block · NA · recruiting
- NCT07229976 — Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03652896 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huazhong University of Science and Technology
- Last refreshed: 29 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652896.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing